CAMBRIDGE, Mass. – January 25, 2021 – Caraway Therapeutics today announced that the Company’s Chief Executive Officer, Martin D. Williams, will present at the Winter Private Company Showcase, co-hosted by Solebury Trout, Oppenheimer and White & Case on Friday, January 29, 2021 at 11am Eastern Time. The presentation will provide an overview of the Company’s unique approach to enhancing endogenous cellular clearance mechanisms as a therapeutic strategy for genetically defined neurodegenerative and rare diseases. Recent progress from Caraway’s TRPML1 and TMEM175 programs will be highlighted.
About Caraway Therapeutics
Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically defined neurodegenerative and rare diseases. The company is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating autophagy and lysosomal function. Caraway is utilizing its unique product engine with proprietary insights into lysosomal function and small molecule ion channel modulation to develop a robust pipeline of precision therapeutic candidates with disease-modifying potential for patients. The company is backed by top-tier investors, including SV Health Investors, AbbVie Ventures, MRLV Fund, Amgen Ventures, Dementia Discovery Fund, Alexandria Venture Investments and Eisai Innovation.
Caraway is based in Cambridge, MA. For more information, please visit www.carawaytx.com.
Caroline Rufo, PhD or Kari Watson
firstname.lastname@example.org or email@example.com